A
Alessandra Bearz
Researcher at National Institutes of Health
Publications - 198
Citations - 12644
Alessandra Bearz is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 36, co-authored 177 publications receiving 10767 citations. Previous affiliations of Alessandra Bearz include University of Catania.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal Article
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
Cesare Gridelli,Francesco Perrone,Ciro Gallo,Antonio Rossi,Francesco Scognamiglio,C. Guida,Silvio Monfardini,Giovanni Pietro Ianniello,Vincenza Tinessa,Maria Grazia Caprio,Antonio Santoro,Luigi Maiorino,Massimiliano Santoro,Francovito Piantedosi,L. Brancaccio,Carlo Crispino,S. Cigolari,Maria Di Lanno,Valentina Angelini,Luigi Manzione,Domenico Bilancia,Angelo Dinota,Giuseppe Failla,Rosa Anna Aiello,Paolo Tralongo,F. Figoli,Ludmilla Zuccarino,Tonino Pedicini,Antonio Febbraro,Cesira Zollo,Luciano Frontini,S. Zonato,Giuseppe Azzarello,Orazio Vinante,Federico Castiglione,Gianfranco Porcile,Alessandra Bearz,Roberto Sorio,Maurizio Tonato,S. Darwish,Enzo Veltri,M. D'Aprile,Carlo Curcio,Matteo Vasta,M. Clerici,Gino Luporini,Antonio Farris,Rosario Vincenzo Iaffaioli,Adolfo Favaretto,Giuseppe Gualtieri +49 more
TL;DR: Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall quality of life (QoL) in a multicenter randomized trial that compared vinore lbine treatment with supportive care alone.
Journal ArticleDOI
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D. Ross Camidge,Hye Ryun Kim,Myung-Ju Ahn,James Chih-Hsin Yang,Ji Youn Han,Jong Seok Lee,Maximilian Hochmair,Jacky Yu-Chung Li,Gee Chen Chang,Ki Hyeong Lee,Cesare Gridelli,Angelo Delmonte,Rosario Garcia Campelo,Dong Wan Kim,Alessandra Bearz,Frank Griesinger,Alessandro Morabito,Enriqueta Felip,Raffaele Califano,Sharmistha Ghosh,Alexander I. Spira,Scott N. Gettinger,M. Tiseo,Neeraj Gupta,Jeff Haney,David Kerstein,Sanjay Popat +26 more
TL;DR: Among patients with ALK‐positive NSCLC who had not previously received an ALK inhibitor, progression‐free survival was significantly longer among patients who received brigatinib than among those who received crizotinib.
Journal ArticleDOI
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon,Benjamin Besse,Benjamin Besse,Todd M. Bauer,Enriqueta Felip,Ross A. Soo,D. Ross Camidge,Rita Chiari,Alessandra Bearz,Chia-Chi Lin,Shirish M. Gadgeel,Gregory J. Riely,Eng Huat Tan,Takashi Seto,Leonard P. James,Jill S. Clancy,Antonello Abbattista,Jean-Francois Martini,Joseph Chen,Gerson Peltz,Holger Thurm,Sai-Hong Ignatius Ou,Alice T. Shaw +22 more
TL;DR: Overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer and safety data for all treated patients (EXP1-6) are presented.
Journal ArticleDOI
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
Sai-Hong Ignatius Ou,Jin Seok Ahn,Luigi De Petris,Ramaswamy Govindan,James Chih-Hsin Yang,Brett G.M. Hughes,Hervé Lena,Denis Moro-Sibilot,Alessandra Bearz,Santiago Viteri Ramirez,Tarek Mekhail,Alexander I. Spira,Walter Bordogna,Bogdana Balas,Peter N. Morcos,Annabelle Monnet,Ali Zeaiter,Dong Wan Kim +17 more
TL;DR: Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases, and the cumulative CNS progression rate was lower than the cumulative non-CNS progression rate at 12 months for all patients.